DNA vaccines expressing the envelope (Env) of the human immunodeficiency virus type 1 (HIV-1) have been relatively ineffective at generating high-titer, long-lasting, neutralizing antibodies. In this study, DNA vaccines were constructed to express the gp120 subunit of Env from the isolate HIV-1 R2 using both wild-type and codon-optimized gene sequences. Three copies of the murine C3d were added to the carboxyl terminus to enhance the immunogenicity of the expressed fusion protein.
INTRODUCTION
At the end of 2003, approximately 42 million people were infected and living with the human immunodeficiency virus type 1 (HIV-1), the pathogen associated with the onset of acquired immunodeficiency syndrome (AIDS). 1 Greater than 95% of new HIV infections occurred in developing countries (70% men, 30% women). AIDS is a state of immunodeficiency that weakens a patient's immune system resulting in the development of fatal opportunistic infections. Despite the effectiveness of highly active antiretroviral therapy (HAART), there are several drawbacks that prevent its worldwide use, particularly for individuals in developing nations. 2-4 Therefore, one of the long-term goals of HIV/AIDS research has been the development of a safe and effective vaccine.
The induction of highly cross-reactive neutralizing antibodies is one of the goals of HIV vaccine development. A variety of vaccine strategies using envelope immunogens has failed to induce antibodies capable of neutralizing cross-clade, primary isolates. 5-7 The elicitation of antibodies directed against Env appears to be a critical component of an AIDS vaccine. 8 Crossreactive antibodies that neutralize primary isolates have been infrequently described in sera from donors infected with HIV-1. However, reference serum prepared from a donor infected in the United States with a clade B strain of HIV-1 has neutralizing antibodies that cross-react extensively with primary HIV-1 isolates of various clades. 9-11 The donor (HNS2) had a longterm nonprogressive HIV-1 infection for more than 10 years. 12 Relatively cross-reactive antibodies that neutralize primary isolates have been described in sera from other donors with long-term nonprogressive HIV-1 infections. 13 The Env R2 , expressed from one of the env genes cloned from patient HNS2, can be neutralized by sera from patients infected with HIV-1 from clades A, B, C, D, and F, as well as circulating recombinant forms (CRF). 12 Virions pseudotyped with the Env R2 can mediate CD4-independent infection. In addition, these viruses are sensitive to neutralization by a panel of monoclonal antibodies that recognizes conformation epitopes in envelope. 14 A rare mutation found in the crown of the V3 loop, a proline (P) and methionine (M) (nucleotide position 313/314), appears responsible for the uncommon neutralization sensitivity phenotype and the capacity of this envelope to mediate CD4-independent infection. 14 Recently, Dong et al. 15 expressed the Env R2 from a Venezuelan equine encephalitis (VEE) replicon and elicited high titer neutralizing antibodies in mice and rabbits following immunization. These properties are consistent with the possibility that the Env R2 expresses one or more neutralization epitopes that are responsible for induction of cross-reactive neutralizing antibodies in the donor of HNS2.
DNA vaccination (genetic vaccination) induces protective immunity against a variety of pathogens. [16] [17] [18] [19] These genetic vaccines consist of eukaryotic expression plasmids that are inoculated into target cells in the skin, muscle, or mucosal surfaces of a host and are translated into proteins. 7,20 DNA vaccination effectively induces both humoral and cellular immune responses to immunogens from diverse infectious agents. 5,17-19,21-23 The use of a variety of HIV envelope immunogens has failed to induce antibodies capable of neutralizing more than a fraction of primary isolates. 5,7 Unlike most immunogens, multiple DNA immunizations are required to elicit even modest titers of neutralizing antibody to the HIV envelope glycoprotein. 17, 18, 22, [24] [25] [26] [27] [28] [29] [30] However, the elicitation of neutralizing antibodies appears to be a critical component of any HIV vaccine. 20, 31 One approach advanced in our laboratory to enhance the immunogenicity to HIV-1 Env is the use of the complement protein, C3d, as a molecular adjuvant. Conjugation of multiple copies of C3d to an antigen enhances the immunogenicity of low or nonimmunogenic antigens. 27, 32 C3d, when fused to an antigen, but not when coinoculated, enhances the total IgG titer against the conjugated protein. 27,32 Antibodies directed against (1) the hemagglutinin of influenza or measles virus, 22,33,34 (2) the merozoite surface antigen, MSP1.19, of Plasmodium yoelii ,35 (3) the capsular polysaccharide of serotype 14 Streptococcus pneumonia ,36,37 (4) the hepatatis B surface antigen (L. Wang, personal communication) were increased between 1 and 3 logs following immunization with DNA-expressing C3d-conjugated antigens. The addition of three copies of murine or human C3d to soluble forms of HIV-1 envelope accelerated both the onset and the avidity maturation of antibody in vaccinated mice and enhanced neutralizing antibody titers compared to mice vaccinated with antigen alone. 24, 26, 29, 30 In addition, titers of neutralizing antibodies to influenza or measles viruses were increased using DNA plasmids expressing C3d-fused hemagglutinin. 21, 33, 34 Interestingly, the precise mechanism of C3d enhancement is unclear, however, C3d appears to enhance antibody and cellular responses via both CR2-dependent and -independent mechanisms. 38 Therefore, the goal of this study was to analyze the effectiveness of the unique V3 sequence from Env R2 introduction into the env genes from two prototype R5 strains to determine if the Pro-Met mutation would confer increased neutralization capacity following DNA vaccination. These envelopes were expressed from either wild-type or synthetic codon-optimized sequences alone or in conjunction with mC3d 3 and then analyzed for both total IgG and neutralization.
MATERIALS AND METHODS
Plasmid vector DNA pTR600, a eukaryotic expression vector, has been described previously. 24, 26, 30, 33, 39 Briefly, the vector was constructed to contain the cytomegalovirus immediate-early promoter (CMVIE) plus intron A (IA) for initiating transcription of eukaryotic inserts and the bovine growth hormone polyadenylation signal [BGH poly(A)] for termination of transcription. The vector contains the ColE1 origin of replication for prokaryotic replication and the kanamycin resistance gene (Kan r ) for selection in antibiotic media.
Construction of DNA vaccines
Previously, gp120 ADA and gp120 89.6 expression plasmids and gp120 ADA -C3d 3 and gp120 89.6 -C3d 3 flusion constructs using wild-type Env gene sequences have been characterized. 26, 29, 30 Briefly, the envelope sequences from the isolate, HIV-1 R2 , encoding almost the entire gp120 region were cloned into the pTR600 vaccine vector using unique restriction endonuclease sites (Fig. 1A) . C3d sequences were cloned in frame at the 3 end of the gp120 gene. The first 32 amino acids were deleted from the N-terminus of each sgp120 and replaced with a leader sequence from the trypsin plasminogen activator (tpA). The vectors expressing sgp120-mC3d 3 fusion proteins were generated by cloning three tandem repeats of the mouse homologue of C3d in frame with the sgp120-expressing DNA. The construct design was based upon Dempsey et al. 32 with glycine/serine linkers {(G 4 S) 2 } between gp120 and each C3d repeat. 26,29,30 A second gp120 R2 gene was synthesized to encode for the gp120 molecule (amino acids 1-526) using codons for enhanced expression in mammalian cells (GeneArt, Regensburg, Germany). In addition, the synthetic gp120 R2 gene was cloned in frame with the mC3d 3 gene. 14,40 Lastly, oligonucleotides were constructed to introduce into the gp120 ADA or gp120 89.6 genes a proline/methionine (Pro-Met) at amino acids 313/314 in the V3 loop by polymerase chain reaction (PCR)-based mutagenesis (Fig. 1B) . The same mutations were introduced into the gp120 ADA -C3d 3 -DNA and gp120 89.6 -C3d 3 -DNA.
The plasmids were amplified in Escherichia coli strain DH5 , purified using endotoxin-free, anion-exchange resin columns (Qiagen, Valencia, CA) and stored at -20°C in dH 2 O. Plasmids were verified by appropriate restriction enzyme digestion and gel electrophoresis. Purity of DNA preparations was determined by optical density reading at 260 and 280 nm and, therefore, each DNA vaccine inoculation contained >50 fg/ g of endotoxin per DNA inoculation.
Transfections and expression analysis
The human embryonic kidney cell line 293T (5 × 10 5 cells/transfection) was transfected with 1 g of DNA using 12% lipofectamine according to the manufacturer's guidelines (Life Technologies, Grand Island, NY). Supernatants were collected and stored at -20°C. Cell lysates were collected in 300 l of 1% Triton-X buffer and stored at -20°C. Quantitative antigen capture ELISAs were conducted as previously described. 24,26,29 Alternatively, monoclonal antibodies (IgG 1b12 , F105, 2F5, 17b, 48d) 25,41-43 were used to detect the fusion proteins in ELISA. All DNA expressing gp120 from wild-type sequences produced equal amounts of protein ( 1 g/ l), which was three to four times higher than the amount of protein expressed from gp120-mC3d 3 -DNA. DNA expressing the same molecules from codon-optimized gene sequences elicited 10 times higher amounts of protein (data not shown). Similar results were observed for wild-type and codon-optimized Env gene sequences from isolates HIV-1 ADA and HIV-1 89. 6 . The introduction of the Pro-Met mutation at amino acids 313/314 did not affect protein expression (data not shown).
Iodination and binding of sgp120 to cell surface receptors
The gp120 or gp120-mC3d 3 molecules were labeled using Iodobead (Pierce, Rockford, IL) iodination of 10 g of protein for 5 min in a 150 l volume of phosphate-buffered saline (PBS), using 250 Ci of Na 125 I preincubated for 5 min with one Iodobead. 44 125 I incorporation rates of greater than approximately 50% resulted in oxidative destruction of protein that was no longer capable of binding any receptor. Radiolabeled proteins were purified from free Na 125 I by separation through a 0.3-ml Dowex column prepared in a 1-ml syringe and preequilibrated in a mixture containing 50 mM HEPES (pH 7.4), 5 mM MgCl 2 , 1 mM CaCl 2 , 1% bovine serum albumin (BSA), and 150 mM NaCl. Protein fractions were eluted in the void volume of the column, and the fractions containing peaks of labeled protein were combined. The integrity of gp120 after radiolabeling was verified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography.
Env binding assays were performed by resuspending HOS CCR5 + or HOS CXCR4 + cells in 75 l of HEPES binding buffer [50 mM HEPES (pH 7.4), 5 mM MgCl 2 , 1 mM CaCl 2 , 5% BSA, 0.1% NaN 3 ]. Labeled proteins were added to cells in 25 l of binding buffer for a total volume of 100 l. Cells were incubated at room temperature (RT) for 1 hr. Unbound radioactivity was removed by filtering cells through 25-mm filters (Whatman, Clifton, NJ) presoaked in 0.2% polyethyleneimine (Sigma, St. Louis, MO) and thoroughly washed. Filters were counted in a gamma counter and results are expressed as counts per minute. For competition experiments, radiolabeled gp120 and gp120-mC3d 3 proteins were incubated with monoclonal antibody 17b (1 g/ l) for 1 hr at 37°C. Cells were pelleted and washed with PBS and then analyzed in a gamma counter.
Animals and DNA immunizations
Six-to 8-week-old BALB/c mice (Harlan Sprague Dawley, Indianapolis, IN) were vaccinated intradermally using particle bombardment (gene gun) inoculations. Gene gun immunizations were performed on shaved abdominal skin of anethesized mice as described previously. 26, 34, 45, 46 Mice were immunized with two gene gun doses containing 1 g of DNA per 0.5 mg of approximately 1 m gold beads (Bio-Rad, Hercules, CA) at a helium pressure setting of 400 psi.
Immunological assays
An endpoint ELISA was performed to assess the titers of anti-Env IgG in immune serum 28 using matched, recombinant HIV-1 gp120 protein to coat plates purified as previously described. 24 Mouse sera from vaccinated mice were allowed to bind and subsequently were detected by antimouse IgG conjugated to horseradish peroxidase (Southern Biotechnology, Birmingham, AL). Endpoint titers were considered positive that were 2-fold higher than background. Similar ELISAs were performed to determine the isotype of IgG (IgG 1 or IgG 2a ) or other immunoglobulin classes, IgM, IgE, and IgA, elicited by vaccination. All assays were performed in triplicate.
Avidity ELISAs were performed similarly to serum antibody determination ELISAs up to the addition of samples and standards. 26,28-30,33,34,47-52 Samples were diluted to give similar concentrations of specific IgG by OD. Plates were washed three times with 0.05% PBS-Tween 20. Different concentrations of the chaotropic agent sodium thiocyanate (NaSCN) in PBS were then added (0, 1, 1.5, 2, 2.5, and 3 M NaSCN). Plates were allowed to stand at room temperature for 15 min and then washed six times with PBS-Tween 20. Subsequent steps were performed similarly to the serum antibody determination ELISA. Percent of initial IgG was calculated as a percent of the initial OD. All assays were done in triplicate.
Neutralization of virus infection
Pseudotyped viruses were prepared by transfection of 293T cells with pNL4-3.luc.E-R and envelope-expressing plasmids, as previously described. 53,54 Infectivity and neutralization assays were carried out using HOS CD4 + CCR5 + , HOS CD4 + CXCR4 + , HOS CCR5 + , or HOS CXCR4 + cells. 12,40,53-55 Infectivity was determined on the basis of luminescence measured 3 days after infection. As previously described, neutralization assays were performed by preincubation of serial serum with pseudotyped viruses [ADA, 89.6, R2 (clade B), 92UG029 (clade A), or 92BR025 (clade C)] prior to cell infection. 12,53,54 The average dilution of 50% of the mean luminescence from three independent experiments was determined for each serum sample for each pseudotyped virus. In addition, the nonspecific neutralizing titer from naive, age-matched mice at each dilution was subtracted from each value.
Statistics
For statistical analysis, a Student's t test was employed. The difference between gp120 fused to multiple copies of murine C3d and gp120 alone or fused to murine C3d was determined. Differences were considered statistically significant when p < 0.05.
RESULTS

Binding of monoclonal antibodies to envelope
The gp120 R2 was more easily recognized by the monoclonal antibodies 17b and 48d, 43,57-61 which recognize CD4-induced epitopes, compared to gp120 ADA or gp120 89.6 (Table 1) .
Similar results were observed with gp120 ADA(Pro-Met) and gp120 89.6(Pro-Met) . The addition of mC3d 3 did not inhibit the binding by any of the monoclonal antibodies (Table 1 ). All the gp120 molecules were recognized by the monoclonal antibodies F105 and 1b12 and the monoclonal antibody 2F5, which maps to a linear sequence in gp41, did not recognize any of the expressed gp120 envelopes. The addition of sCD4 to gp120 ADA or gp120 89.6 enhanced the binding of 17b and 48d (Table 1) , however, sCD4 did not increase the binding of these antibodies to gp120 R2 . Therefore, CD4-induced epitopes are exposed on the gp120 R2 molecule, as well as gp120, incorporating the Pro-Met mutation, which are recognized by antibodies that usually bind only following exposure to hCD4.
Binding of gp120 to cell surface receptors
Radiolabeled gp120 R2 directly bound to cells expressing hCCR5, but not to cells expressing hCXCR4 ( Table 2 ). The addition of mC3d 3 to the 3 end of the fusion protein did not affect the binding of gp120 R2 to the cell surface chemokine receptors. gp120 ADA or gp120 89.6 did not bind to coreceptor expressing cells, however, both molecules did bind to cells expressing hCD4 (data not shown). However, envelopes with the Pro-Met mutation efficiently bound to appropriate coreceptor expressing cells. The addition of anti-hCCR5 antibodies (Table 2) or nonradioactive gp120 R2 , gp120 ADA(Pro-Met) , or gp120 89.6(Pro-Met) (data not shown) significantly (p > 0.05) competed with the radiolabeled proteins.
Antibody response to gp120-mC3d 3 
DNA immunizations
As previously reported, 24,26,29,30,33 mice vaccinated with DNA plasmid (2 g) expressing the gp120 R2 -mC3d 3 from wild-type sequences (day 1 and then boosted at weeks 4 and 8) raised detectable titers of anti-Env antibody (1:6200 at week 8) (Fig. 2A) . Few, if any, anti-Env R2 antibodies were detected in mice vaccinated with gp120 R2 -DNA following three inoculations. In contrast, mice vaccinated with DNA expressing gp120 R2 or gp120 R2 -mC3d 3 from codonoptimized sequences (2 g) had detectable titers (both IgG 1 and IgG 2a ) after the first immunization, which were boosted following additional inoculations (Fig. 2A) . Mice vaccinated with gp120 R2 -mC3d 3 -DNA using codon-optimized sequences had an average peak titer that was greater than 1 log higher (>1:000,000 at week 8) than mice vaccinated with gp120 R2 -mC3d 3 -DNA using wild-type sequences (<1:10,000 at week 8). In addition, mice vaccinated with gp120 R2 -DNA using codon-optimized sequences elicited similar, or in some cases higher, titers than C3d-conjugated forms ( Fig. 2A) . Similar results were observed in collected sera from mice vaccinated with vaccines using the gp120 ADA , gp120 ADA(Pro-Met) , gp120 89.6 , or gp120 89.6(Pro-Met) (Fig. 2B and C) . The introduction of the Pro-Met mutation into the gp120 ADA or gp120 89.6 did not appear to affect the titers of IgG elicited in vaccinated mice, regardless of whether the proteins were expressed from wild-type or codon-optimized sequences. Therefore, at this dose of inoculum, the C3d enhancement effect was masked when the fused protein was expressed from DNA using codon-optimized gene sequences.
Interestingly, mice vaccinated with DNA expressing non-C3d versions of each gp120 molecule had detectable titers of IgG 1 , but little or no titers of IgG 2a at week 10 (data not shown). However, mice vaccinated with DNA expressing C3d-conjugated gp120 molecules elicited similar titers of IgG 1 and IgG 2a . The use of codon-optimized gene sequences did not alter the ratio between the two immunoglobulin classes, even though the overall titer was approximately 1 log higher.
The avidity of the antibody generated with DNA expressing gp120-mC3d 3 was consistently higher than antisera from gp120-DNA vaccinated mice. Antisera from mice vaccinated with gp120-DNA had an ED 50 of 0.5 M. However, mice vaccinated with DNA expressing gp120-mC3d 3 had an ED 50 of 1.5 M (week 10). Similar results were observed from mice vaccinated with DNA expressing gp120 ADA(Pro-Met) or gp120 89.6(Pro-Met) . These results indicate that the Pro-Met mutation did not affect the maturation of the anti-Env antibody.
Envelopes with the Pro-Met mutation elicit cross-reactive neutralizing antibodies
Mice vaccinated with DNA expressing gp120 using wild-type gene sequences were unable to neutralize viral infection (week 10) due to the lack of anti-Env antibodies (Fig. 2) , whereas, the addition of C3d raised antibodies capable of neutralizing homologous infection (1:16 dilution) (Table 3) . However, DNA plasmid expressing neither gp120 ADA -mC3d 3 , nor gp120 89.6 -mC3d 3 was able to elicit antibodies that significantly prevented heterologous viral infection.
Mice vaccinated with DNA expressing gp120 R2 from codon-optimized gene sequences elicited high titers of neutralizing antibodies against HIV-1 R2 (1:80 dilution). The addition of C3d to gp120 raised the neutralizing antibodies (1:256 dilution) that neutralized homologous virus infection. Furthermore, conjugation of C3d to gp120 R2 broadens the neutralizing capacity of the antisera, preventing virus infection by the heterologous viruses (Table 3 ). Mice vaccinated with DNA expressing gp120 ADA ± mC3d 3 from codon-optimized gene sequences did not broaden the number of viruses neutralized compared to non-C3d-conjugated gp120 ADA . In addition, mice vaccinated with gp120 ADA(Pro-Met) -mC3d 3 -DNA using codon-optimized genes neutralized both homologous and heterologous viruses (Table 3) . Overall, codon optimization or C3d fusion enhanced the titer of neutralizing antibody. However, the induction of the highest titers of cross-reactive, neutralizing antibodies was elicited by C3d coupled to gp120 R2 or to a gp120 incorporating the unique V3 loop mutations found in Env R2 .
DISCUSSION
In this study, DNA plasmids expressing the envelope from the HIV-1 R2 (isolated from donor HNS2) were used to elicit high titer neutralizing antibodies in vaccinated mice (Table 3) . Serum collected from donor HNS2, a long-term nonprogressor, had antibodies that neutralized primary isolates from a broad range of clades. 15 Interestingly, when the Env R2 is pseudotyped onto a virion, the virus is easily neutralized by anti-HIV sera. 14 Therefore, we hypothesized that the gp120 subunit of Env R2 would elicit cross-reactive neutralizing antibodies expressed from a DNA plasmid following vaccination. To enhance titers of anti-Env antibodies by DNA plasmids expressing gp120 R2 , two strategies were employed: (1) codon optimization of the gp120 R2 gene sequences 62,63 and (2) the use of C3d conjugated to gp120 R2 . 24, 26, 29, 30, 64 Each strategy raised high titer anti-Env antibodies that neutralized homologous HIV-1 R2 viral infection, however, the combination of both codon optimization and C3d to gp120 R2 elicited the broadest neutralizing antibody responses ( Table 3 ).
The Env R2 has a rare mutation in the proximal limb of variable region 3 (V3), amino acids 313-314, Pro-Met. 12,54 The neutralization sensitivity of this envelope has been mapped to this unique region of V3. 14 Recently, Zhang et al. 14 demonstrated that the Env R2 was highly sensitive to neutralization by the monoclonal antibody 19b, which is directed against conformation-sensitive epitopes at the crown of the V3 loop. The binding of specific monoclonal antibodies that recognize CD4-induced epitopes is also dependent on this region (Table 1) . A unique double turn is located at the apex of the V3 loop (GPGRAF) that is highly conserved across clade B isolates. 65 A proline residue immediately 5 to the V3 loop apex could significantly alter the structure of the V3 loop, resulting in exposure of the coreceptor binding site. 66 Unlike most HIV-1 envelopes, the gp120 R2 specifically bound to cells expressing hCCR5 ( Table 2 ), indicating that the conformation of this envelope allows for coreceptor binding without the necessity of prior hCD4 interaction. The exposure of the coreceptor binding site in Env R2 could explain the enhanced sensitivity of this envelope to neutralization.
The Env R2 , or the unique sequences located in Env R2 , could be an attractive immunogen for inducing neutralizing antibodies in humans following vaccination. 67,68 Recently, Dong et al. 15 demonstrated that neutralizing antibodies can be induced using a VEE replicon system expressing the Env R2 . Therefore, in this study, the unique sequence at the crown of the V3 loop in Env R2 was introduced into two envelopes that do not normally elicit high titer neutralizing antibodies. Even though there are differences in the V3 loop sequences of Env R2 and Env ADA (four amino acids) or Env 89.6 (eight amino acids), the apex sequence is conserved in all three envelopes (Fig. 1 ). Mice vaccinated with each of these mutated envelopes did not dramatically enhance the neutralizing titers to homologous virus challenge regardless of whether the genes were expressed from wild-type or codon-optimized sequences (Table 3) . However, the addition of C3d to these envelopes not only enhanced the anti-Env titer, but also broadened the number of viruses neutralized by collected sera (Table 3 ).
This study confirms that C3d can act as a molecular adjuvant to enhance antibody responses to the conjugated antigen. However, the mechanism(s) of action of C3d are still unclear. Recently, we demonstrated that unexpectedly, C3d can function as an effective adjuvant in the absence of CD21/35 expression. 38 C3d has been shown to bind to CD21 (CR2) resulting in the coligation of CD19 to CD21, which, in turn, stimulates a signaling cascade that leads to the proliferation of B lymphocytes. 32 However, the only direct evidence supporting this conclusion was that pretreatment of mice with an antibody against CD21 suppressed the effect elicited by C3d. Although anti-CD21 monoclonal treatment is known to inhibit humoral immune responses to a variety of antigens, 69-71 anti-CD21 monoclonal antibody treatment may have effects on B cell function beyond blocking C3d binding. 72 Therefore, C3d may enhance immune responses, including cellular responses, 24,64 by multiple mechanisms. C3d may possibly enhance the uptake and processing of conjugated antigens by B cells, which results in enhanced antigen presentation. Also, the process by which C3d enhances neutralizing antibodies remains unclear, however, this enhancement is dependent on the neutralization potential of the conjugated immunogen. The gp120 proteins with a modified V3 loop used in this study and trimeric forms of Env (gp140) 24 both elicited neutralizing antibodies that were enhanced by conjugation to C3d.
Despite the delayed appearance of neutralizing antibody in infected patients 47 (6-8 months to achieve affinity maturation), this component of the immune response appears important in controlling infection. Immunogens that elicit high titer anti-envelope antibodies are one component of a vaccine needed for a multifaceted immune response against HIV-1. Even though DNA-expressing gp120 molecules conjugated to C3d or expressed using codonoptimized gene sequences elicited higher titer anti-Env antibodies, only mice vaccinated with Env R2 had cross-reactive neutralizing antibodies (Table 3) . Interestingly, the introduction of the unique Pro-Met mutation into a prototypic R5 envelope (ADA) or a prototypic dual tropic envelope (89.6) enhanced the neutralizing capacity of these proteins. Mice vaccinated with DNA using codon-optimized gp120 ADA(Pro-Met) genes fused to mC3d 3 elicited 4-to 8-fold high titers of neutralizing antibodies than nonmutated envelopes (Table 3) . Therefore, the ProMet mutation in Env R2 is most likely responsible for the constitutively exposed coreceptor binding site on the molecule. In addition, envelope immunogens incorporating the Env R2 sequence induced broadly cross-reactive neutralizing antibodies following immunization.
FIG. 1.
(A) The first schematic represents the secreted gp120 form of the envelope used as a vaccine insert. The second schematic represents the sgp120-C3d 3 construct used as a vaccine insert. The third schematic represents the C3d 3 construct used as a vaccine insert. Linkers composed of two repeats of four glycines and a serine {(G 4 S) 2 } were fused at the junctures between gp120 and C3d and between each C3d repeat. (B) V3 loop sequence representing R2, ADA, and 89.6. The superscript Pro-Met represents proline and methionine mutation introduced into gp120 ADA and gp120 89.6 . Undelined amino acids indicate additional amino acids that differed with the R2 sequence.
FIG. 2.
Anti-Env IgG raised by DNAs expressing gp120 in gene gun vaccinated mice. Mice were primed with DNA at day 0 and boosted at weeks 4 and 8. Sera were obtained from mice every 2 weeks. Serum collected at the indicated times from each mouse was assayed for specific IgG levels by ELISA. Plates (96-well) were coated with recombinant gp120 R2 protein. 
